What are peptides, actually?

The answer, no warm-up

Take amino acids — the twenty building blocks of biology — and link a few together in a chain. That's a peptide. Two links counts. Fifty still counts. Past that, chemists usually start saying "protein".

The difference isn't cosmetic. A short chain doesn't fold into a complex three-dimensional machine the way a protein does. It works differently: as a message, not as machinery. Most peptides in your body are exactly that — signals. The molecule goes out, delivers an instruction to a receptor, gets broken down.

You already run on peptides

Insulin, managing your blood sugar. Oxytocin. Ghrelin, reminding you to eat. Endorphins. None of this is lab exotica — it's your body's standard chemistry, working right now.

That's why pharma watches this class so closely: these are molecules your body already speaks fluently. By 2021 more than 80 peptide drugs had been approved by regulators worldwide, and the count keeps climbing.

Why everyone suddenly talks about them

Honest answer: money and results. GLP-1 peptide drugs changed how diabetes and obesity are treated, and attention on the whole category jumped an order of magnitude. In parallel there's a research market — compounds studied in laboratories that are not medicines.

Here's the part worth keeping straight. "Peptide" is a chemical class, not a quality mark and not a promise of effect. An approved drug went through clinical trials. A research compound did not. The molecules can look similar; the status is fundamentally different.

What this means in our catalogue

The materials in the Moscow Peptides catalogue are research reagents for laboratory work, not for human use. For every compound we state what the published literature contains, label the evidence level, and draw no conclusions the literature doesn't support.